A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
This study has been completed.
Sponsor:
Pfizer
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00163098
First received: September 8, 2005
Last updated: October 12, 2006
Last verified: October 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Disease, Chronic Obstructive |
Drug: UK-369,003 |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease |
Resource links provided by NLM:
MedlinePlus related topics:
COPD (Chronic Obstructive Pulmonary Disease)
Exercise and Physical Fitness
U.S. FDA Resources
Further study details as provided by Pfizer:
Eligibility| Ages Eligible for Study: | 35 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- GOLD criteria 2 to 4
- 10 pack year history of smoking
Exclusion Criteria:
- Women of child bearing potential
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00163098
Locations
| Argentina | |
| Pfizer Investigational Site | |
| Unknown, Buenos Aires, Argentina | |
| Pfizer Investigational Site | |
| Ciudad de Cordoba, Cordoba, Argentina, CP 5016 | |
| Pfizer Investigational Site | |
| San Miguel de Tucuman, Pcia de Tucuman, Argentina | |
| Pfizer Investigational Site | |
| San Miguel de Tucuman, Pcia de Tucuman, Argentina, 4000 | |
| Pfizer Investigational Site | |
| Rosario, Santa Fé, Argentina, 2000 | |
| Pfizer Investigational Site | |
| Buenos Aires, Argentina, 1272 | |
| Pfizer Investigational Site | |
| Buenos Aires, Argentina, 1427 | |
| Pfizer Investigational Site | |
| Ciudad de Beurnos Aires, Argentina, C1425DQi | |
| Pfizer Investigational Site | |
| Ciudad de Buenos Aires, Argentina, C1115AAB | |
| Pfizer Investigational Site | |
| Ciudad de Buenos Aires, Argentina, C1416DRV | |
| Pfizer Investigational Site | |
| Ciudad de Buenos Aires,, Argentina, (C1425DTG) | |
| Pfizer Investigational Site | |
| Provincia de Buenos Aires, Argentina, (1605) | |
| Australia, New South Wales | |
| Pfizer Investigational Site | |
| Camperdown, New South Wales, Australia, 2050 | |
| Pfizer Investigational Site | |
| Darlinghurst, New South Wales, Australia, 2010 | |
| Australia, Queensland | |
| Pfizer Investigational Site | |
| Chermside,, Queensland, Australia, 4032 | |
| Australia, South Australia | |
| Pfizer Investigational Site | |
| Adelaide, South Australia, Australia, 5000 | |
| Australia, Victoria | |
| Pfizer Investigational Site | |
| Melbourne, Victoria, Australia, 3004 | |
| Australia, Western Australia | |
| Pfizer Investigational Site | |
| Perth, Western Australia, Australia, 6000 | |
| Germany | |
| Pfizer Investigational Site | |
| Giessen, Germany, 35392 | |
| Pfizer Investigational Site | |
| Greifestein, Germany, 35753 | |
| India | |
| Pfizer Investigational Site | |
| Cochin, Kerala, India, 682026 | |
| Pfizer Investigational Site | |
| Mumbai, Maharashtra, India, 400016 | |
| Pfizer Investigational Site | |
| Pune, Maharashtra, India, 411 019 | |
| Pfizer Investigational Site | |
| Chennai, Tamilnadu, India, 600116 | |
| Pfizer Investigational Site | |
| Vellore, Tamilnadu, India, 632002 | |
| United Kingdom | |
| Pfizer Investigational Site | |
| Papworth Everard, Cambridgeshire, United Kingdom, CB3 8RE | |
| Pfizer Investigational Site | |
| Glasgow, United Kingdom, G11 6NT | |
| Pfizer Investigational Site | |
| Newcastle Upon Tyne, United Kingdom, NE7 7DN | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00163098 History of Changes |
| Other Study ID Numbers: | A3711028 |
| Study First Received: | September 8, 2005 |
| Last Updated: | October 12, 2006 |
| Health Authority: | Germany: Ethics Commision |
Additional relevant MeSH terms:
|
Chronic Disease Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive |
Lung Diseases, Obstructive Disease Attributes Pathologic Processes Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 19, 2013